Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind Placebo-Controlled Trial of the Synbiotic Compound Probio-Tec ABCG for Schizophrenia Patients With and Without Elevated Markers of Gastrointestinal Inflammation

NCT04226898 is registered in ClinicalTrials.gov with Sheppard Pratt Health System as lead sponsor.

NCT NCT04226898
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04226898 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind Placebo-Controlled Trial of the Synbiotic Compound Probio-Tec ABCG for Schizophrenia Patients With and Without Elevated Markers of Gastrointestinal Inflammation
Lead sponsor
Sheppard Pratt Health System
Phase
Phase 2
Overall status
Recruiting
Start date
February 21, 2022
Completion date
December 31, 2027
Enrollment
68 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

schizoaffective disorder, schizophrenia